Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 14;2(4):531-535.
doi: 10.6051/j.issn.2224-3992.2013.02.247.

Plasma insulin, glucose, IGF-I, IGF-II, and IGFBP-3 and risk of recurrent colorectal adenomas

Melissa Kang  1 , Anne F Peery  1 , Cameron Locklear  2 , Joseph A Galanko  1 , Robert S Sandler  1 , Temitope O Keku  1
Affiliations

Plasma insulin, glucose, IGF-I, IGF-II, and IGFBP-3 and risk of recurrent colorectal adenomas

Melissa Kang et al. J Gastroenterol Hepatol Res. .

Abstract

Aim: Insulin and insulin-like growth factors (IGF's) are associated with an increased risk of colorectal adenomas. The association with recurrent adenomas is inadequately studied. We prospectively examined the relationship between insulin biomarkers and the risk of recurrent adenomas.

Materials and methods: Our analysis included 167 subjects with one or more adenomas detected on a baseline colonoscopy who had a surveillance colonoscopy within three to five years. We measured serum biomarkers in all subjects at baseline. ELISA was used to measure fasting plasma insulin, IGF-I, IGF-II, and IGF binding protein-3. The hexokinase assay was used to measure fasting plasma glucose by and immuno-turbidimetric assay to measure hemoglobin A1C.

Results: Subjects with recurrent adenomas were more likely to be male, overweight and have ≥3 adenomas at baseline. We found no significant associations between insulin (OR=1.6, 95% CI 0.7-3.5), glucose (OR=1.4, 95% CI 0.7-3.1), IGF-I (OR=0.7, 95% CI 0.3-1.5), IGF-II (OR=1.0, 95% CI 0.5-2.3), IGFBP-3 (OR=0.1, 95% CI 0.5-2.1), or anthropometric measures and recurrent adenomas.

Conclusion: Our results do not support a role for insulin biomarkers and recurrent colorectal adenomas.

Keywords: colorectal adenoma; insulin; insulin-like growth factor.

PubMed Disclaimer

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62:10–29. - PubMed
    1. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: A review. The American journal of clinical nutrition. 2007;86:s836–842. - PubMed
    1. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nature reviews Cancer. 2004;4:579–591. - PubMed
    1. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: A meta-analysis of prospective studies. The American journal of clinical nutrition. 2007;86:556–565. - PubMed
    1. Kabat GC, Kim MY, Strickler HD, Shikany JM, Lane D, Luo J, Ning Y, Gunter MJ, Rohan TE. A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. British journal of cancer. 2012;106:227–232. - PMC - PubMed

LinkOut - more resources